Quantitative Systems Pharmacology: Applications and Adoption in Drug Development
暂无分享,去创建一个
[1] SRB Allerheiligen,et al. Impact of Modeling and Simulation: Myth or Fact? , 2014, Clinical pharmacology and therapeutics.
[2] K. Boye,et al. Cardiovascular outcomes associated with a new once‐weekly GLP‐1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis , 2011, Diabetes, obesity & metabolism.
[3] John D. Davis,et al. A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations , 2014, CPT: pharmacometrics & systems pharmacology.
[4] Malcolm Rowland,et al. Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.
[5] Peter Falkai,et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. , 2006, The New England journal of medicine.
[6] Tarek A. Leil,et al. Quantitative Systems Pharmacology can reduce attrition and improve productivity in pharmaceutical research and development , 2014, Front. Pharmacol..
[7] Robert P Kocher,et al. The calculus of cures. , 2014, The New England journal of medicine.
[8] B. Agoram,et al. Evaluating Systems Pharmacology Models Is Different From Evaluating Standard Pharmacokinetic–Pharmacodynamic Models , 2014, CPT: pharmacometrics & systems pharmacology.
[9] J. Rullmann,et al. Systems biology for battling rheumatoid arthritis: application of the Entelos PhysioLab platform. , 2005, Systems biology.
[10] M. Bullano,et al. The impact of initial statin treatment decisions on cardiovascular outcomes in clinical care settings: estimates using the Archimedes Model , 2012, ClinicoEconomics and outcomes research : CEOR.
[11] H. Kitano,et al. Software for systems biology: from tools to integrated platforms , 2011, Nature Reviews Genetics.
[12] U. Nielsen,et al. Multiscale Kinetic Modeling of Liposomal Doxorubicin Delivery Quantifies the Role of Tumor and Drug-Specific Parameters in Local Delivery to Tumors , 2012, CPT: pharmacometrics & systems pharmacology.
[13] Albert Wang,et al. Virtual Systems Pharmacology (ViSP) software for simulation from mechanistic systems-level models , 2014, Front. Pharmacol..
[14] Hugh A. Barton,et al. Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury , 2014, Front. Pharmacol..
[15] J. Arrowsmith,et al. A decade of change , 2012, Nature Reviews Drug Discovery.
[16] L Zhang,et al. Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review , 2011, Clinical pharmacology and therapeutics.
[17] Tanya Cashorali,et al. Causal Modeling Using Network Ensemble Simulations of Genetic and Gene Expression Data Predicts Genes Involved in Rheumatoid Arthritis , 2011, PLoS Comput. Biol..
[18] R. Iyengar,et al. Computation as the Mechanistic Bridge Between Precision Medicine and Systems Therapeutics , 2013, Clinical pharmacology and therapeutics.
[19] M. Riggs,et al. Predicting Nonlinear Changes in Bone Mineral Density Over Time Using a Multiscale Systems Pharmacology Model , 2012, CPT: pharmacometrics & systems pharmacology.
[20] D. Lauffenburger,et al. Input–output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data , 2009, Molecular systems biology.
[21] U. Iloeje,et al. Modeling effects of SGLT‐2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes , 2014, Diabetes, obesity & metabolism.
[22] H Geerts,et al. A Quantitative System Pharmacology Computer Model for Cognitive Deficits in Schizophrenia , 2013, CPT: pharmacometrics & systems pharmacology.
[23] Daniel C Kirouac,et al. Computational Modeling of ERBB2-Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors , 2013, Science Signaling.
[24] Paul Morgan,et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. , 2012, Drug discovery today.
[25] S. Visser,et al. Implementation of Quantitative and Systems Pharmacology in Large Pharma , 2014, CPT: pharmacometrics & systems pharmacology.
[26] J. Arrowsmith. Trial watch: Phase III and submission failures: 2007–2010 , 2011, Nature Reviews Drug Discovery.
[27] Neil Benson,et al. Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacology , 2013, Interface Focus.
[28] P. Watkins,et al. A Mechanistic Model of Drug-Induced Liver Injury Aids the Interpretation of Elevated Liver Transaminase Levels in a Phase I Clinical Trial , 2014, CPT: pharmacometrics & systems pharmacology.
[29] Melvin E. Andersen,et al. Modeling Drug- and Chemical-Induced Hepatotoxicity with Systems Biology Approaches , 2012, Front. Physio..
[30] Richard Kahn,et al. Relationship of Insulin Resistance and Related Metabolic Variables to Coronary Artery Disease: A Mathematical Analysis , 2009, Diabetes Care.
[31] Hugo Geerts,et al. Quantitative systems pharmacology as an extension of PK/PD modeling in CNS research and development , 2013, Journal of Pharmacokinetics and Pharmacodynamics.
[32] MC Peterson,et al. FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment? , 2015, CPT: pharmacometrics & systems pharmacology.
[33] CM Friedrich,et al. A model qualification method for mechanistic physiological QSP models to support model‐informed drug development , 2016, CPT: pharmacometrics & systems pharmacology.
[34] Marc R Gastonguay,et al. Multiscale Physiology‐Based Modeling of Mineral Bone Disorder in Patients With Impaired Kidney Function , 2012, Journal of clinical pharmacology.
[35] Ravi Iyengar,et al. Systems Pharmacology of Adverse Event Mitigation by Drug Combinations , 2013, Science Translational Medicine.
[36] Fergal P. Casey,et al. Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis , 2013, BMC Bioinformatics.
[37] K Gadkar,et al. A Six‐Stage Workflow for Robust Application of Systems Pharmacology , 2016, CPT: pharmacometrics & systems pharmacology.
[38] Matthew M Riggs,et al. A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling. , 2010, Bone.
[39] Elisa Binda,et al. High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease. , 2014, Rheumatology.
[40] L. Kuepfer. Towards whole-body systems physiology , 2010, Molecular systems biology.
[41] P Vicini,et al. Systems Pharmacology for Drug Discovery and Development: Paradigm Shift or Flash in the Pan? , 2013, Clinical pharmacology and therapeutics.
[42] Adam Cohen,et al. Pharmacokinetic and Pharmacodynamic Data to be Derived from Early-Phase Drug Development , 2008, Clinical pharmacokinetics.
[43] O Demin,et al. Systems Pharmacology Models Can Be Used to Understand Complex Pharmacokinetic-Pharmacodynamic Behavior: An Example Using 5-Lipoxygenase Inhibitors , 2013, CPT: pharmacometrics & systems pharmacology.
[44] Jan van den Berg,et al. Systems Biology and Pharmacology , 2010, Clinical pharmacology and therapeutics.
[45] P. Roberson,et al. Proteasomal Degradation of Runx2 Shortens Parathyroid Hormone-induced Anti-apoptotic Signaling in Osteoblasts , 2003, Journal of Biological Chemistry.
[46] C. Allaart,et al. Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint. , 2011, Arthritis and rheumatism.
[47] James Lu,et al. An In-Silico Model of Lipoprotein Metabolism and Kinetics for the Evaluation of Targets and Biomarkers in the Reverse Cholesterol Transport Pathway , 2014, PLoS Comput. Biol..
[48] Christian Sonesson,et al. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis , 2016, Cardiovascular Diabetology.
[49] Gary R. Mirams,et al. Application of cardiac electrophysiology simulations to pro-arrhythmic safety testing , 2012, British journal of pharmacology.
[50] B. Hendriks,et al. Impact of Tumor HER2/ERBB2 Expression Level on HER2-Targeted Liposomal Doxorubicin-Mediated Drug Delivery: Multiple Low-Affinity Interactions Lead to a Threshold Effect , 2013, Molecular Cancer Therapeutics.
[51] Yoram Rudy,et al. Rate Dependence and Regulation of Action Potential and Calcium Transient in a Canine Cardiac Ventricular Cell Model , 2004, Circulation.
[52] Neil Benson,et al. Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and Development , 2011, Pharmaceutical Research.
[53] L. Sobrinho,et al. A minimal mathematical model of calcium homeostasis. , 2002, The Journal of clinical endocrinology and metabolism.
[54] V. Grantcharova,et al. Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis , 2009, Science Signaling.
[55] Paul B Watkins,et al. Linking physiology to toxicity using DILIsym®, a mechanistic mathematical model of drug-induced liver injury. , 2014, Biopharmaceutics & drug disposition.
[56] H. Mistry,et al. An in silico canine cardiac midmyocardial action potential duration model as a tool for early drug safety assessment. , 2012, American journal of physiology. Heart and circulatory physiology.
[57] Saskia Vosslamber,et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients , 2012, Arthritis Research & Therapy.
[58] L. Sequist,et al. 246PA META-ANALYSIS OF BIOMARKERS IN THREE RANDOMIZED, PHASE 2 STUDIES OF MM-121, A LIGAND-BLOCKING ANTI-ERBB3 ANTIBODY, IN PATIENTS WITH OVARIAN, LUNG, AND BREAST CANCERS. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[59] D. Lauffenburger,et al. Physicochemical modelling of cell signalling pathways , 2006, Nature Cell Biology.
[60] Peter Junker,et al. CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic ‘window of opportunity’ , 2014, Arthritis Research & Therapy.
[61] R. Iyengar,et al. Merging Systems Biology with Pharmacodynamics , 2012, Science Translational Medicine.
[62] J. Arrowsmith,et al. Trial Watch: Phase II and Phase III attrition rates 2011–2012 , 2013, Nature Reviews Drug Discovery.
[63] Samik Ghosh,et al. Connecting the dots: role of standardization and technology sharing in biological simulation. , 2010, Drug discovery today.
[64] Henggui Zhang,et al. The canine virtual ventricular wall: a platform for dissecting pharmacological effects on propagation and arrhythmogenesis. , 2008, Progress in biophysics and molecular biology.
[65] D. Noble,et al. Systems Biology: An Approach , 2010, Clinical pharmacology and therapeutics.
[66] Kapil Gadkar,et al. Systems Modeling Applied to Candidate Biomarker Identification , 2011 .
[67] P Vicini,et al. A Mechanistic, Multiscale Mathematical Model of Immunogenicity for Therapeutic Proteins: Part 1—Theoretical Model , 2014, CPT: pharmacometrics & systems pharmacology.
[68] D. Fell,et al. Using a mammalian cell cycle simulation to interpret differential kinase inhibition in anti-tumour pharmaceutical development. , 2006, Bio Systems.
[69] P Vicini,et al. A Mechanistic, Multiscale Mathematical Model of Immunogenicity for Therapeutic Proteins: Part 2—Model Applications , 2014, CPT: pharmacometrics & systems pharmacology.
[70] Vincent Lemaire,et al. Modeling the interactions between osteoblast and osteoclast activities in bone remodeling. , 2004, Journal of theoretical biology.
[71] Oleg Demin,et al. Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development. , 2011, Drug discovery today.
[72] A. Rostami-Hodjegan,et al. Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology , 2012, Clinical pharmacology and therapeutics.
[73] A. Henney,et al. The virtual liver: a multidisciplinary, multilevel challenge for systems biology , 2012, Wiley interdisciplinary reviews. Systems biology and medicine.
[74] Saroja Ramanujan,et al. Evaluation of HDL-modulating interventions for cardiovascular risk reduction using a systems pharmacology approach[S] , 2016, Journal of Lipid Research.